SCHEMBL1676134

SCHEMBL1676134

CS(=O)(=O)N(CC(=O)O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2C=Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
EGFR P00533 1/20 0.34
SDHB P21912 1/20 0.34
MDM2 Q00987 1/20 0.33
ERBB2 P04626 1/20 0.33
MMP2 P08253 2/20 0.33
MMP9 P14780 2/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
MARS1 P56192 1/20 0.33
DAGLA Q9Y4D2 1/20 0.32
S1PR1 P21453 1/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676130 1.00 PTGDR2 (0.35) PTGDR2SMN1; SMN2CNR1CNR2EGFR
SCHEMBL1676152 0.93 EGFR (0.34) PTGDR2CNR1CNR2EGFRMDM2
SCHEMBL1676155 0.93 EGFR (0.34) PTGDR2CNR1CNR2EGFRMDM2
SCHEMBL1676351 0.90 PPARD (0.39) PTGDR2CNR1CNR2EGFRMDM2
SCHEMBL1676353 0.90 PPARD (0.39) PTGDR2CNR1CNR2EGFRMDM2
SCHEMBL1676776 0.86 KDM4E (0.37) PTGDR2CNR1CNR2EGFRSDHB
SCHEMBL1676775 0.86 KDM4E (0.37) PTGDR2CNR1CNR2EGFRSDHB
SCHEMBL1481287 0.84 RAB9A (0.44) SMN1; SMN2EGFRMARS1KDM4EEGLN1
SCHEMBL1481289 0.84 RAB9A (0.44) SMN1; SMN2EGFRMARS1KDM4EEGLN1
SCHEMBL1677240 0.83 CNR1 (0.37) PTGDR2CNR1CNR2EGFRMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE PTGDR2 2266/4885SMN1; SMN2 4417/4885CNR1 3344/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE PTGDR2 2266/4885SMN1; SMN2 4417/4885CNR1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.